Finally some good news for AstraZeneca (AZN). After a torrid few months, during which its share price dropped by a fifth, Astra has announced results from a final phase drugs trial at the annual conference of the American Society of Hematology.
IC TIP:
Buy
at
4118p
Tagrisso - widely cited by analysts as one of Astra’s top blockbuster drug hopes - has successfully demonstrated superiority over chemotherapy in treating non-small cell lung cancer patients. The drug reduced the risk of disease progression by 70 per cent and is now expected to become the standard second-line treatment for lung cancer patients with a specific genetic mutation.
